The NMI is a member of the Innovation Alliance Baden-Württemberg. It is involved in application-oriented research at the interface between the life sciences and material science. An interdisciplinary team of scientists is developing new technologies for companies and public research sponsors in the areas of Pharma and Biotech, Biomedicine and Materials Science, and Material Analysis and Electron Microscopy.
The Multiplex Immunoassays Group at the NMI has strong expertise in multiplex miniaturized immunoassays. We are experts in assay development and validation, with unique capabilities for large-scale screening projects with tens of thousands of samples for biomarker discovery and qualification. One strong focus of our group, is serological testing for antibodies following pathogen infection (SARS-CoV-2, hepatitis viruses, MTB etc).
This position is available to start immediately.
Recent research during the SARS-CoV-2 pandemic has uncovered the role of cytokines and autoantibodies in disease progression, establishing a causal link between the expression of different cytokines/autoantibodies and increased disease severity. Our in-house developed assay is currently used in multiple national screening projects, identifying SARS-CoV-2 antibodies and seroprevalence. To run parallel to this assay and to enhance it further, we seek to develop a new immunoassay for autoantibodies.
In this thesis, you would develop an assay to identify cytokine/autoantibody signatures of SARS-CoV-2 infection in serum and saliva. You would also have the opportunity to take part in the development of immunoassays for other infectious viruses (i.e. Rhinovirus) as part of a collaborative team effort.
Your contact person
Frau Katja Rösslein